Fineline Cube

Follow:
14437 Articles
Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development
CompanyDeals

Zhejiang Jolly Pharma Invests in Lingyi Biotech for Gene Therapy Development

Johnson & Johnson's Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
CompanyDrug

Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication

LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline
CompanyDeals

LTZ Therapeutics Secures $40M Series A+ to Advance Immunotherapy Pipeline

Amgen Announces $900M Investment to Expand Ohio Manufacturing
Company

Amgen Announces $900M Investment to Expand Ohio Manufacturing

Johnson & Johnson's Tremfya Approved by EC for Ulcerative Colitis Treatment
CompanyDrug

Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1
CompanyDrug

Keymed Biosciences Gains NMPA Approval for Phase I/II Study of CM518D1

Akeso's Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC
CompanyDrug

Akeso’s Ivonescimab Approved by NMPA for First-Line PD-L1-Positive NSCLC

Explore the latest insights on Lifeon Pharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lifeon Pharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
CompanyDrug

Hefei Lifeon Gains NMPA Approval for Nexletol Clinical Trials in China

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141
CompanyDrug

Fujian Cosunter Gains NMPA Clearance for Phase II HBV Study of GST-HG131 and GST-HG141

Anhui Anke's Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials
CompanyDrug

Anhui Anke’s Allogeneic CAR-T Therapy UTAA09 Approved for r/r B-ALL Trials

Juventas Cell Therapy's CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis
CompanyDrug

Juventas Cell Therapy’s CNCT 19 Gains NMPA Approval for Refractory Lupus Nephritis

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis
CompanyDrug

TYK Medicines Submits Pre-NDA Package for Asandeutertinib in NSCLC Brain Metastasis